The thin red line: Angiogenesis in normal and malignant hematopoiesis

Experimental Hematology

Volumn 28, Issue 9, 2000, Pages 993-1000

  Bertolini, Francesco ^a   Mancuso, Patrizia ^a   Gobbi, Alberto ^a   Pruneri, Giancarlo ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Angiogenesis; Hematopoiesis; Leukemia; Lymphoma; Vasculogenesis

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FUMAGILLOL CHLOROACETYLCARBAMATE; MARIMASTAT; MONOCLONAL ANTIBODY LM 609; PENICILLAMINE; RITUXIMAB; THALIDOMIDE; VINBLASTINE;

ANGIOGENESIS; ARTICLE; CELL DIFFERENTIATION; CLINICAL TRIAL; HEMATOPOIESIS; HUMAN; MYELOPROLIFERATIVE DISORDER; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; STEM CELL;

EID: 0033806603     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(00)00508-7     Document Type: Review

References (97)

1. Keller G., Lacaud G., Robertson S. Development of the hematopoietic system in the mouse. Exp Hematol. 27:1999;777.
2. Wagner R.C. Endothelial cell embryology and growth. Adv Microcirc. 9:1980;45.
3. Shalaby F., Ho J., Stanford W.L.et al. A requirement for flk-1 in primitive and definitive hematopoiesis and vasculogenesis. Cell. 89:1997;981.
4. Schuh A.C., Faloon P., Hu Q.L., Bhiman M., Choi K. In vitro hematopoietic and endothelial potential of flk-1-/- embryonic stem cells and embryos. Proc Natl Acad Sci U S A. 96:1999;2159.
5. Hidaka M., Stanford W.L., Bernstein A. Conditional requirement for the flk-1 receptor in the in vitro generation of early hematopoietic cells. Proc Natl Acad Sci U S A. 96:1999;7370.
6. Drake C.J., Fleming P.A. Vasculogenesis in the day 6.5 to 9.5 mouse embryo. Blood. 95:2000;1671.
7. Cloche, an early acting zebrafish gene, is required by both the endothelial and hematopoietic lineages. Development. 121:1995;1845.
8. Gering M., Rodaway A.R., Gottgens B., Patient R.K., Green A.R. The SCL gene specifies hemangioblast development from early mesoderm. EMBO J. 17:1998;4029.
9. Choi K., Kennedy M., Kazarov A., Papadimitriou J.C., Keller G. A common precursor for hematopoietic and endothelial cells. Development. 125:1998;725.
10. Nishikawa S.I., Nishikawa S., Hirashima M., Matsuyoshi N., Kodama H. Progressive lineage analysis by cell sorting and culture identifies FLK+VE-Cadherin+ cells at a diverging point of endothelial and hematopoietic lineages. Development. 125:1998;1747.
11. Nishikawa S.I., Nishikawa S., Kawamoto H.et al. In vitro generation of lymphohematopoietic cells from endothelial cells purified from murine embryos. Immunity. 8:1998;761.
12. Ogawa M., Kizumoto M., Nishikawa S., Fujimoto T., Kodama H., Nishikawa S.I. Expression of alpha4-integrin defines the earliest precursor of hematopoietic cell lineage diverged from endothelial cells. Blood. 93:1999;1168.
13. Jaffredo T., Gautier R., Eichmann A., Dieterlen-Lievre F. Intraaortic hemopoietic cells are derived from endothelial cells during ontogeny. Development. 125:1998;4575.
14. Ziegler B.L., Valtieri M., Almeida Porada G.et al. KDR receptor. a key marker defining hematopoietic stem cells Science. 285:1999;1553.
15. Holash J, Masonpierre PC, Compton D, et al. (1999) Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284:1994.
16. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:1996;353.
17. Asahara T., Nurohara T., Sullivan A.et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 275:1997;964.
18. Shi Q., Rafii S., Hong-de Wu M.et al. Evidence for circulating bone marrow derived endothelial cells. Blood. 92:1998;362.
19. Asahara T., Masuda H., Takahashi T.et al. Bone marrow origin of endothelial progenitor cells resposnsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 85:1999;221.
20. Lin Y., Weisdorf D.J., Solovey A., Hebbel R.P. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest. 105:2000;71.
21. Peichev M., Naiyer A.J., Pereira D.et al. Expression of VEGFR-2 and AC133 by circulating human CD34+ cells identifies a population of functional endothelial precursors. Blood. 95:2000;952.
22. Lemischka I. The power of stem cells reconsidered? Proc Natl Acad Sci U S A. 96:1999;14193.
23. Weissman I.L. Stem cells. units of development, units of regeneration, and units in evolution Cell. 100:2000;157.
24. Bjornson C.R., Rietze R.L., Reynolds B.A., Magli M.C., Vescovi A.L. Turning brain into blood. a hematopoietic fate adopted by adult neural stem cells in vivo Science. 283:1999;534.
25. Jackson K.A., Mi T., Goodell M.A. Hematopoietic potential of stem cells isolated from murine skeletal muscle. Proc Natl Acad Sci U S A. 96:1999;14482.
26. Ferrari G., Cusella-De Angelis G., Coletta M.et al. Muscle regeneration by bone marrow-derived myogenic progenitors. Science. 279:1998;1528.
27. Kopen G.C., Prockop D.J., Phinney D.G. Marrow stromal cell migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. Proc Natl Acad Sci U S A. 96:1999;10711.
28. Petersen B.E., Bowen W.C., Patrene K.D.et al. Bone marrow as a potential source of hepatic oval cells. Science. 284:1999;1168.
29. Theise N.D., Badve S., Saxena R.et al. Derivation of hepatocytes from bone marrow cells in mice after radiation-induced myeloablation. Hepatology. 31:2000;235.
30. Gussoni E., Soneoka Y., Strickland C.D.et al. Dystrophin expression in the mdx mouse restored by stem cell transplantation. Nature. 401:1999;390.
31. Giu L., Chang L., Solovey A.et al. P1H12 as an embryonic endothelial-endothelial adhesion molecule and possible hemangioblast marker. Blood. 92:1998;172a. (abstr).
32. De Angelis L., Berghella L., Coletta M.et al. Skeletal myogenic progenitors originating from embryonic dorsal aorta coexpress endothelial and myogenic markers and contribute to postnatal muscle growth and regeneration. J Cell Biol. 147:1999;869.
33. Rafii S. Circulating endothelial precursors. mystery, reality and promise J Clin Invest. 105:2000;17.
34. Kalka C., Masuda H., Takahashi T.et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A. 97:2000;3422.
35. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57.
36. Perez-Atayde A.R., Sallan S.E., Tedrow U., Connors S., Allred E., Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol. 150:1997;815.
37. Vacca A., Ribatti D., Presta M.et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood. 93:1999;3064.
38. Vacca A., Ribatti D., Ruco L.et al. Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphoma. Br J Cancer. 79:1999;965.
39. Hussong J.W., Rodgers G.M., Shami P.J. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood. 95:2000;309.
40. Padro T., Ruiz S., Bieker R.et al. Increased angiogenesis in the bone marrow of patients with acute leukemia. Blood. 95:2000;2637.
41. Pruneri G., Bertolini F., Soligo D.et al. Angiogenesis in myelodysplastic syndromes. Br J Cancer. 81:1999;1398.
42. Ramanujan S., Koenig G.C., Padera T.P., Stoll B.R., Jain R.K. Local imbalance of proangiogenic and antiangiogenic factors. a potential mechanism of focal necrosis and dormancy in tumors Cancer Res. 60:2000;1442.
43. Aguayo A., Estey E., Kantarjian H.et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood. 94:1999;3717.
44. Molica S., Vitelli G., Levato D., Gandolfo G.M., Liso V. Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukemia. Br J Haematol. 107:1999;605.
45. Salven P., Teerenhovi L., Joensuu H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood. 90:1997;3167.
46. Bertolini F., Paolucci M., Peccatori F.et al. Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br J Haematol. 106:1999;504.
47. Salven P., Teerenhovi L., Joensuu H. A high pretreatment serum basic-fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma. Blood. 94:1999;3334.
48. Bellamy W.T., Richter L., Frutiger Y., Grogan T.M. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res. 59:1999;728.
49. Fusetti L., Gobbi A., Rabascio C.et al. Human myeloid and lymphoid malignancies in the NOD/SCID mouse model. frequency of apoptotic cells in solid tumors, efficiency and speed of engraftment correlate with vascular endothelial growth factor production Cancer Res. 60:2000;2527.
50. Foss H.D., Araujo I., Demel G., Klotzbach H., Hummel M., Stein H. Expression of vascular endothelial growth factor in lymphomas and Castleman's disease. J Pathol. 183:1997;44.
51. Anderson I.C., Mari S.E., Broderick R.J., Mari B.P., Shipp M.A. The angiogenic factor interleukin 8 is induced in non-small cell lung cancer/pulmonary fibroblast cocultures. Cancer Res. 60:2000;269.
52. Dankbar B., Padro T., Leo R.et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood. 95:2000;2630.
53. Yamaguchi H., Ishii E., Saito S.et al. Umbilical vein endothelial cells are an important source of c-kit and stem cell factor which regulate the proliferation of haemopoietic progenitor cells. Br J Haematol. 94:1996;606.
54. Solanilla A., Grosset C., Lemercier C.et al. Expression of Flt3-ligand by the endothelial cell. Leukemia. 14:2000;153.
55. Fiedler W, Graeven U, Ergun S, et al. (1997) Vascular endothelial growth factor, a possible paracrine factor in human acute myeloid leukemia. Blood 89:1870.
56. Allouche M., Bayard F., Clamens S., Fillola G., Sie P., Almaric F. Expression of basic fibroblast growth factor (b-FGF) and FGF-receptors in human leukemic cells. Leukemia. 9:1995;77.
57. Veikkola T., Karkkainen M., Claesson-Welsh L., Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 60:2000;203.
58. Ferrara N., Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med. 5:1999;1359.
59. Folkman J. Incipient angiogenesis (edtiorial). J Natl Cancer Inst. 92:2000;94.
60. Pezzella F., Pastorino U., Tagliabue E.et al. Non small cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis Am J Pathol. 151:1997;1417.
61. Pezzella F., Di Bacco A., Andreola S., Nicholson A.G., Pastorino U., Harris A.L. Angiogenesis in primary lung cancer and lung secondaries. Eur J Cancer. 32:1996;2494.
62. Pezzella F., Manzotti M., Di Bacco A.et al. Evidence for a novel non-angiogenic pathway in breast cancer metastasis. Lancet. 355:2000;1787.
63. Holash J, Maisonpierre PC, Compton D, et al. (1999) Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284:1994.
64. Li C., Shan S., Huang Q.et al. Initial stages of tumor cell-induced angiogenesis. evaluation via skin window chambers in rodent models J Natl Cancer Inst. 92:2000;143.
65. Maniotis A.J., Folberg R., Hess A.et al. Vascular channel formation by human melanoma cells in vivo and in vitro. vasculogenic mimicry Am J Pathol. 155:1999;739.
66. Folberg J., Hendrix M.J.C., Maniotis A.J. Vasculogenic mimicry and tumor angiogenesis. Am J Pathol. 156:2000;361.
67. McDonald D.M., Munn L., Jain R.K. Vasculogenic mimicry. how convincing, how novel, and how significant Am J Pathol. 156:2000;383.
68. Rajkumar S.V., Fonseca R., Witzig T.E., Gertz M.A., Greipp P.R. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. Leukemia. 13:1999;469.
69. Brem S. Angiogenesis and cancer control. from concept to therapeutic trial Cancer Control JMCC. 6:1999;. n02/cc0605.02. brem/cc0605.02.brem-01.html) available on the Internet at http://www.medscape.com/Moffitt/CancerControl/1999/v06.
70. D'Amato R.J., Loughnan M.S., Flynn E., Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 91:1994;4082.
71. Sauer H., Günther J., Hescheler J., Wartenberg M. Thalidomide inhibits angiogenesis in embryoid bodies by the generation of hydroxyl radicals. Am J Pathol. 156:2000;151.
72. Singhal S., Mehta J., Desikan R.et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 341:1999;1565.
73. Thomas D.A., Aguayo A., Giles F.J.et al. Thalidomide anti-angiogenesis therapy in Philadelphia-negative myeloproliferative disorders and myelofibrosis. Blood. 94:1999;702a. (abstr).
74. Raza A., Lisak L., Andrews C.et al. Thalidomide produces transfusion independence in patients with long-standing refractory anemias and myelodysplastic syndromes. Blood. 94:1999;661a. (abstr).
75. Slaton J.W., Perrotte P., Inoue K., Dinney C.P.N., Fidler I.J. Interferon-α-mediated down regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res. 5:1999;2726.
76. Pruneri G., Soligo D., Valentini S., Carboni N., Bladini L., Lambertenghi-Deliliers G. Angiogenesis in hairy cell leukemia. Exp Hematol. 27:1999;77a. (abstr).
77. Kaban L.B., Mulliken J.B., Ezekowitz R.A., Ebb D., Smith P.S., Folkman J. Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a. Pediatrics. 103:1999;1145.
78. Iurlaro M., Vacca A., Minischetti M.et al. Antiangiogenesis by cyclosporine. Exp Hematol. 26:1998;1215.
79. Vacca A., Iurlaro M., Ribatti D.et al. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood. 94:1999;4143.
80. Klement G., Baruchel S., Rak J.et al. Continous low-dose therapy with vinblastine and VEGF receptor-2 antibody indices sustained tumor regression without overt toxicity. J Clin Invest. 105:2000;R15.
81. Browder T, Butterfield CE, Kraling BM, et al. (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878.
82. Rocca A., Colleoni M., Nolè F.et al. Low dose oral methotrexate (MTX) and cyclophosphamide (CTX) in metastatic breast cancer (MBC). antitumor activity and correlation with serum vascular endothelial growth factor (VEGF) levels Proc Am Soc Clin Oncol. 18:1999;121a. (abstr).
83. O'Reilly M.S., Wiederschain D., Stetler-Stevenson W.G., Folkman J., Moses M.A. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem. 274:1999;29568.
84. O'Reilly M.S., Bohem T., Shing Y.et al. Endostatin. an endogenous inhibitor of angiogenesis and tumour growth Cell. 88:1977;277.
85. Wen W., Moses M.A., Wiederschain D., Arbiser J.L., Folkman J. The generation of endostatin is mediated by elastase. Cancer Res. 59:1999;6052.
86. O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J (1999) Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 285:1926.
87. Bertolini F., Fusetti L., Mancuso P.et al. The anti-angiogenic drug endostatin induces tumor stabilization after chemo- or anti-CD20 therapy of a NOD/SCID mouse model of human high-grade non-Hodgkin's lymphoma. Blood. 96:2000;282.
88. Bohem T., Folkman J., Browder T., O'reilly M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 390:1997;404.
89. Perletti G., Concari P., Giardini R.et al. Antitumor activity of endostatin against carcinogen-induced rat primary mammary tumors. Cancer Res. 60:2000;1793.
90. Dias S., Zhu Z., Wu Y., Witte L., Hicklin D.J., Rafii S. Expression of VEGF and its receptor VEGFR-2 by human leukemia cells generates an autocrine loop that mediates cell growth and migration. Proc Am Assoc Cancer Res. 41:2000;792. (abstr).
91. Asano M., Yukita A., Matsumoto T., Kondo S., Suzuki H. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121. Cancer Res. 55:1995;5296.
92. Fong T.A.T., Shawver L.K., Li S.et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 59:1999;99.
93. Aoki Y., Tosato G. role of vascular endothelial growth factor/vascular permeability factor in the pathogenesis of Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphomas. Blood. 94:1999;4247.
94. Harris A.L. Antiangiogenesis for cancer therapy. Lancet. 349(suppl. II):1997;13.
95. Cao Y., Cao R. Angiogenesis inhibited by drinking tea. Nature. 398:1999;381.
96. Yang C.S., Wang Z.Y. Tea and cancer (review). J Natl Cancer Inst. 85:1993;1038.
97. Bertolini F., Fusetti L., Rabascio C., Cinieri S., Martinelli G., Pruneri G. Inhibition of angiogenesis and induction of endothelial and tumor cell apoptosis by green tea in animal models of human high-grade non-Hodgkin's lymphoma. Leukemia. in press:2000.